



For two hundred years we've been waiting for better treatments for Parkinson's Disease. The man with the vision, the positive personal agenda and 20 years of experience in Pharmaceuticals has a plan - and an offer almost too good to be true.

“In many ways Parkinson’s is a sleeping dragon, with seemingly limited interest to the media, the public or the pharmaceuticals industry; the majority diagnosed are elderly and largely unseen. The dragon is now stirring... there’s talk of a pandemic, with an accompanying care crisis. WellumPhoenix, working with the PD community, will be ready.”

David Jones

Patient-led, impatience-driven



David Jones, MBA, PhD, PWP - Man with plan

It was David's wife who pointed out that he was uniquely positioned to make a genuine difference to the PD community. Having watched Parkinson's destroy his father - an Olympic speed skater - when David was diagnosed and offered the same limited drug choice, he realised just how slow progress was. Over 30 years, he has worked for many big pharmas, he understands their rules and how to build a better business model working differently within these rules. WellumPhoenix is the first pharma business with 'community benefit status' in the US.



Gaynor Edwards, PWP - Word Up

A former journalist and marketer, Gaynor is another PWP - person with Parkinson's - on the management team. Having founded a charity for Young Onset Parkinson's, she first met David through the PD community.

Being a patient and new to the pharma world, she is mindful of clearly and concisely presenting the relevant information to the potential customer. "This is what the community has been waiting for... the treatments essential to us today fund the research, leading to better therapies for tomorrow. It's the perfect circle," she says.



Ken Kubota, BSc - Stateside science

Ken has supported WellumPhoenix and been David's wingman from the word 'go'. With over 20 years of combined experience in software and neuroscience, he will ensure best use of all technologies available - resulting in greater economy and efficiency for this ground-breaking company.

He says, "This is our chance to genuinely improve our health-care system, producing better outcomes."

Ken has operated at board level since '96 for names such as Microsoft Corp., Michael J Fox Foundation and RosettaMD.



Nick Williams, PhD - Op Gun

The simplicity and sheer beauty of David's idea saw Nick volunteer to help get the project off the ground. He provides WellumPhoenix with the calm, clear-thinking needed to ensure that the business will follow best commercial practice while always remaining true to its patient-led ethos.

Having worked with David before, Nick is the ultimate sounding board, managing marketing and operations. "It's rare in this industry that you get to put the end-user before the shareholder. WellumPhoenix will lead by example," he says.

Like people with Parkinson's, the revolutionary thinkers that make up the WellumPhoenix team come from many backgrounds and bring their own expertise to the group. With an ethos of doing things differently, WellumPhoenix will benefit from creativity and technology as well as pharmacology.



Robert Taylor, MBA, BSc - The Biz

Robert brings with him a wealth of commercial experience both at home and overseas - having

worked across Europe and Africa.

Solution-driven, Robert is one of several from David's contact book who didn't need asking twice to help. "Surely no one in our industry can question David's motive for setting up WellumPhoenix. He is addressing a very clear need with a social enterprise model that plugs the gap perfectly between commerce and charity. He's absolutely the right man for the job," he says.



Graham Howell, ACA - Money Man

A long-term friend of David's, currently residing in France, Graham is another willing recruit for the

WellumPhoenix cause. His two decades of experience, working with entrepreneurs and senior professional managers, in dynamic fast growing businesses and international companies in Europe and Asia will prove invaluable.

Graham is not part of the Pharma world and so brings with him a refreshing perspective, along with a talent for bridging the gap between Finance and Operations.



Malcolm Barratt-Johnson, MB.BS, BSc (Hons), FRSB, CBiol, - Medic Major

Malcom's CV runs for several pages - and that's the bullet point short version. He is a physician with over 18 years pharmaceutical experience in Medical and Regulatory affairs. Having worked as a consultant and advisor for some of the biggest names at home and abroad, WellumPhoenix is delighted to have his input. Six of the top ten Pharmaceutical Companies are featured on the aforementioned CV. He advises both biotech and generic sectors, making him a perfect fit for the PD problem.



Jon Stamford, PhD - The Brain

Jon Stamford knows more about PD than most and is one of the proactive elders of the community.

A little over a decade ago he was diagnosed with the condition, having spent the previous two decades as a researcher studying the dopaminergic system. He knows about Parkinson's inside and out. An advocate of patient involvement and keen to encourage researchers to talk to those with the condition, he admits he was (in the mirror) the first person with Parkinson's he met.

This is perhaps a sad reflection of what we're up against.